Page 53 - GPD-3-3
P. 53

Gene & Protein in Disease                                         Phage therapy for Mycobacterium infections



            79.  Diacon AH, Guerrero-Bustamante CA, Rosenkranz B,   90.  Dunne M, Hupfeld M, Klumpp J, Loessner MJ. Molecular
               Rubio Pomar FJ, Vanker N, Hatfull GF. Mycobacteriophages   basis  of bacterial host interactions by  gram-positive
               to treat tuberculosis: Dream or delusion?  Respiration.   targeting bacteriophages. Viruses. 2018;10(8):397.
               2022;101(1):1-15.
                                                                  doi: 10.3390/v10080397
               doi: 10.1159/000519870
                                                               91.  Johansen MD, Alcaraz M, Dedrick RM,  et al.
            80.  Guerrero-Bustamante CA, Dedrick RM, Garlena RA,   Mycobacteriophage-antibiotic therapy promotes enhanced
               Russell  DA,  Hatfull  GF. Toward  a  phage Cocktail  for   clearance of drug-resistant  Mycobacterium abscessus.  Dis
               tuberculosis: Susceptibility and tuberculocidal action   Model Mech. 2021;14(9):dmm049159.
               of mycobacteriophages against diverse  Mycobacterium
               tuberculosis strains. mBio. 2021;12(3):e00973-21.     doi: 10.1242/dmm.049159
                                                               92.  Senhaji-Kacha A, Esteban J, Garcia-Quintanilla M.
               doi: 10.1128/mBio.00973-21
                                                                  Considerations for phage therapy against  Mycobacterium
            81.  Myers JA. Can tuberculosis be eradicated?  Dis Chest.   abscessus. Front Microbiol. 2020;11:609017.
               1963;43:327-329.
                                                                  doi: 10.3389/fmicb.2020.609017
               doi: 10.1378/chest.43.3.327
                                                               93.  Li Q, Zhou M, Fan X, Yan J, Li W, Xie J. Mycobacteriophage
            82.  Fish W. Presidential address to preventive medicine section.   SWU1 gp39 can potentiate multiple antibiotics against
               R Soc Health J. 1957;77(7):340-343.                Mycobacterium  via  altering  the  cell  wall  permeability.  Sci
               doi: 10.1177/146642405707700704                    Rep. 2016;6:28701.
            83.  Wulandari DA, Hartati YW, Ibrahim AU, Pitaloka DAE,      doi: 10.1038/srep28701
               Irkham. Multidrug-resistant tuberculosis. Clin Chim Acta.   94.  Hatfull GF. Phage Therapy for nontuberculous mycobacteria:
               2024;559:119701.                                   Challenges and opportunities. Pulm Ther. 2023;9(1):91-107.
               doi: 10.1016/j.cca.2024.119701                     doi: 10.1007/s41030-022-00210-y
            84.  Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new   95.  Dedrick RM, Smith BE, Cristinziano M, et al. Phage therapy
               forms of totally drug-resistant tuberculosis bacilli: Super   of Mycobacterium infections: Compassionate use of phages
               extensively  drug-resistant  tuberculosis  or  totally  drug-  in 20  patients with drug-resistant mycobacterial disease.
               resistant strains in Iran. Chest. 2009;136(2):420-425.  Clin Infect Dis. 2023;76(1):103-112.
               doi: 10.1378/chest.08-2427                         doi: 10.1093/cid/ciac453
            85.  Lange C, Abubakar I, Alffenaar JW, et al. Management of   96.  Dedrick RM, Freeman KG, Nguyen JA, et al. Potent antibody-
               patients with multidrug-resistant/extensively drug-resistant   mediated  neutralization  limits  bacteriophage  treatment  of
               tuberculosis in Europe: A TBNET consensus statement. Eur   a pulmonary Mycobacterium abscessus infection. Nat Med.
               Respir J. 2014;44(1):23-63.                        2021;27(8):1357-1361.
               doi: 10.1183/09031936.00188313                     doi: 10.1038/s41591-021-01403-9
            86.  Hatfull GF, Dedrick RM, Schooley RT. Phage therapy for   97.  Secor PR, Dandekar AA. More than simple parasites: The
               antibiotic-resistant bacterial infections.  Annu Rev Med.   sociobiology of bacteriophages and their bacterial hosts.
               2022;73:197-211.                                   mBio. 2020;11(2):e00041-20.
               doi: 10.1146/annurev-med-080219-122208
                                                                  doi: 10.1128/mBio.00041-20
            87.  Li P, Yong-Ai L, Baowen C, Youlun L, Xiaobing S,   98.  Mushegian AR. Are there 10  virus particles on earth, or
                                                                                        31
               Guo-Zhi  W.  Effect  of  bacteriophage  D29  on  the immune   more, or fewer? J Bacteriol. 2020;202(9):e00052-20.
               function of guinea pigs with a model of tuberculosis. Her
               Med. 2006;0723:767-770.                            doi: 10.1128/jb.00052-20
            88.  Gan Y, Liu P, Wu T, Guo S. Different characteristics between   99.  Hendrix RW, Smith MC, Burns RN, Ford ME, Hatfull GF.
               mycobacteriophage  Chy1 and  D29,  which were classified   Evolutionary relationships among diverse bacteriophages
               as cluster A2 mycobacteriophages. Indian J Med Microbiol.   and prophages: All the world’s a phage. Proc Natl Acad Sci
               2016;34(2):186-192.                                U S A. 1999;96(5):2192-2197.
               doi: 10.4103/0255-0857.180282                      doi: 10.1073/pnas.96.5.2192
            89.  Gan Y, Wu T, Liu P, Guo S. Characterization and classification   100. Hanauer DI, Jacobs-Sera D, Pedulla ML, Cresawn SG,
               of Bo4 as a cluster G mycobacteriophage that can infect and   Hendrix RW, Hatfull GF. Inquiry learning. Teaching
               lyse M. tuberculosis. Arch Microbiol. 2014;196(3):209-218.  scientific inquiry. Science. 2006;314(5807):1880-1881.
               doi: 10.1007/s00203-014-0954-6                     doi: 10.1126/science.1136796


            Volume 3 Issue 3 (2024)                         14                              doi: 10.36922/gpd.2935
   48   49   50   51   52   53   54   55   56   57   58